Sun Pharmaceutical Industries dicovered CEQUA®, a novel therapy for the treatment of dry eye disease.
CEQUA® (cyclosporine ophthalmic solution 0.09% w/v), calcineurin inhibitor immunomodulator which rises tear flow in patients with keratoconjunctivitis sicca (dry eye). It is a new clear preservative-free nanomicelle water solution that helps to improve the penetration of the active ingredient ciclosporin in ocular tissues.
CEQUA® is the first dry ophthalmic treatment delivered with nanoscale NCELL®* technology. This unique NCELL ®* Technology and formulation provides a better dose than cyclosporine emulsion 0.05 percent. It is suitable for patients with inflammatory dry eye disease (DED), the most common disease.
NCELL®* Technology makes use of new encapsulation that surrounds CEQUA® active ingredient ciclosporin allowing cyclosporine to pass through layer of the tear film and releases it into the tissues of the eye where it is most needed.
The existing treatment options for dry eye disease consists of certain limitations resuting in a strong unmet need. The introduction of CEQUA® will become a new treatment option for individuals with this disease.
In the daily practise, cases of dry eye diseases have raised, due to increased screen time and other lifestyle changes, hence resulting for more treatment options.
Global clinical studies have shown that CEQUA® offers quick results and is comfortablly suitable for patients from the start of the treatment.
